Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer.

MLA

Sun, Lova, et al. “Association between Duration of Immunotherapy and Overall Survival in Advanced Non–small-Cell Lung Cancer.” Journal of Clinical Oncology, vol. 41, June 2023, p. 9101. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.9101.

APA

Sun, L., Bleiberg, B. A., Hwang, W.-T., Marmarelis, M. E., Langer, C. J., Singh, A. P., Cohen, R. B., Mamtani, R., & Aggarwal, C. (2023). Association between duration of immunotherapy and overall survival in advanced non–small-cell lung cancer. Journal of Clinical Oncology, 41, 9101. https://doi.org/10.1200/JCO.2023.41.16_suppl.9101

Chicago

Sun, Lova, Benjamin Aaron Bleiberg, Wei-Ting Hwang, Melina Elpi Marmarelis, Corey J. Langer, Aditi Puri Singh, Roger B. Cohen, Ronac Mamtani, and Charu Aggarwal. 2023. “Association between Duration of Immunotherapy and Overall Survival in Advanced Non–small-Cell Lung Cancer.” Journal of Clinical Oncology 41 (June): 9101. doi:10.1200/JCO.2023.41.16_suppl.9101.